IGF1R inhibitors and Akt inhibitors for treatment of cancer

Through the combination therapy of IGF1R inhibitor and Akt inhibitor, especially the combination of lincitinib and MK-2206, the problem of poor resistance and therapeutic effect of cancer treatment in the prior art has been solved, and the coordination of the disease has been significantly improved The therapeutic effects of rectal, ovarian and endometrial cancers, especially in ARID1A and ARID2 mutant cancers.

CN119013023APending Publication Date: 2024-11-22GENOME RES LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033363.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-11
Filing Date
2023-02-10
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing cancer treatments are ineffective in many patients, especially due to drug resistance issues, which lead to poor treatment effects, and targeted therapies for certain types of cancers such as colorectal, ovarian and endometrial cancer. Limited effect.

Method used

Combination therapy of IGF1R inhibitor and Akt inhibitor, especially the combination of lincitinib and MK-2206, is used to treat colorectal cancer, ovarian cancer and endometrial cancer. Through synergistic effects, it enhances the therapeutic effect and reduces the drug's Dosage restriction and toxicity, expanding the scope of treatment.

Benefits of technology

This combination therapy significantly improves the sensitivity to specific types of cancer, especially the therapeutic effects of ARID1A mutant and ARID2 mutant colorectal cancer, enhances reduced cell viability and drug response, and provides better treatment options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005077296700000091
    Figure BDA0005077296700000091
  • Figure BDA0005077296700000101
    Figure BDA0005077296700000101
  • Figure BDA0005077296700000111
    Figure BDA0005077296700000111
Patent Text Reader

Abstract

The present invention relates to combination therapies of IGF1R inhibitors with Akt inhibitors for the treatment of cancer, such as colorectal cancer, ovarian cancer and endometrial cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to combination therapies for the treatment of cancer. Background Art

[0002] Despite advances in cancer treatment, it still has a significant impact on societies, families, and individuals around the world. Cancer is one of the leading causes of death worldwide. According to the U.S. National Cancer Institute, there were 18.1 million new cases of cancer and 9.5 million cancer-related deaths worldwide in 2018. By 2040, the number of new cancer cases is expected to rise to 29.5 million per year, and cancer-related deaths to 16.4 million.

[0003] The use of single-agent targeted therapies for patients with molecularly defined tumors is improving cancer treatment. Despite this, many patients still lack effective treatments, and pre-existing or acquired drug resistance limits the clinical benefit of even our most advanced drugs. Combination therapies using a growing number of targeted anticancer drugs have the potential to overcome resistance, enhance responses to existing drugs, reduce the toxicity of dose-limiting single agents, and expand the therapeutic range of patients. Summary of the invention

[0004] The present invention relates to the use of therapeutic combinations of active ingredients to treat cancer in patients, and in particular to the combination of an IGF1R inhibitor and an Akt inhibitor. As described herein, the inventors have observed a synergistic effect of a combination of an IGF1R inhibitor (such as lincitinib) and an Akt inhibitor (such as MK-2206) in cancer cell lines, particularly colorectal cancer cell lines.

[0005] In a first aspect, the invention may relate to a combination of an IGF1R inhibitor and an Akt inhibitor for use in a method of treating cancer in a patient, wherein the cancer is selected from the group consisting of colorectal cancer, ovarian cancer, and endometrial cancer.

[0006] In some cases, the invention may be directed to an IGF1R inhibitor for use in a method of treating cancer in a patient, wherein the cancer is selected from colorectal cancer, ovarian cancer, and endometrial cancer, and wherein the IGF1R inhibitor is administered to the patient in combination with an Akt inhibitor.

[0007] In some cases, the invention may be directed to an Akt inhibitor for use in a method of treating cancer in a patient, wherein the cancer is selected from colorectal cancer, ovarian cancer, and endometrial cancer, and wherein an IGF1R inhibitor is administered to the patient in combination with an IGF1R inhibitor.

[0008] In some cases, the cancer is colorectal cancer.

[0009] Suitably, the IGF1R inhibitor is selected from linsitinib, GSK1904529A, XL228, BMS-536924, BMS-754807, brigatinib, AXL-1717 and KW-2450; or is an IGF1R antibody. The IGF1R antibody may be an IGF1R monoclonal antibody (mAb). The IGF1R antibody may be selected from teprotumumab, AVE-1642, ganitumab, dalotuzumab, lonigutamabugodotin, A-12, VRDN-002, VRDN-003, ZB-011, BIIB-022, cixutumumab, figitumumab, M-590, robatumumab, XGFR-2, XGFR4, and istiratumab.

[0010] In some cases, the IGF1R inhibitor is selected from linsitinib, GSK1904529A, XL228, BMS-536924, BMS-754807, brigatinib, AXL-1717 and KW-2450. In some cases, the IGF1R inhibitor is selected from linsitinib, GSK1904529A, XL228, BMS-536924, BMS-754807, brigatinib and AXL-1717. In some cases, the IGF1R inhibitor is selected from linsitinib, GSK1904529A, XL228, BMS-536924 and brigatinib. In some cases, the IGF1R inhibitor is selected from linsitinib, GSK1904529A, XL228 and BMS-536924. In some instances, the IGF1R inhibitor is selected from lincitinib and GSK1904529A. In some instances, the IGF1R inhibitor is lincitinib.

[0011] Thus, in some cases, the present invention may relate to a combination of lincitinib and an Akt inhibitor for use in a method of treating colorectal cancer, ovarian cancer, or endometrial cancer. In some cases, the present invention may relate to a combination of AXL-1717 and an Akt inhibitor for use in a method of treating colorectal cancer, ovarian cancer, or endometrial cancer.

[0012] In some cases, the Akt inhibitor is an allosteric Akt inhibitor. In some cases, the Akt inhibitor is an allosteric Akt inhibitor selected from MK-2206, miransertib, and BAY1125976.

[0013] In other instances, the Akt inhibitor is an ATP-competitive Akt inhibitor. In some instances, the Akt inhibitor is an ATP-competitive Akt inhibitor selected from capivasertib, afuresertib, and ipatasertib.

[0014] Suitably, the Akt inhibitor is selected from MK-2206, capasitinib, patasertib, afloresetib, milansetib, uprosertib, triciribine, PTX-200, TAS-117, COTI-2, LY-2503029, MK-4440 and BAY1125976. In some cases, the Akt inhibitor is selected from MK-2206, capasitinib, patasertib, afloresetib, milansetib and BAY1125976. In some cases, the Akt inhibitor is selected from MK-2206, capasitinib, milansetib and BAY1125976. In some cases, the Akt inhibitor is selected from MK-2206, patasertib and afloresetib. In some cases, the Akt inhibitor is MK-2206.

[0015] Thus, the combination used according to the first aspect may be a combination of lincitinib and MK-2206.

[0016] Alternatively, the combination used according to the first aspect may be a combination of BMS-754807 and MK-2206. Alternatively, the combination used according to the first aspect may be a combination of GSK1904529A and MK-2206. Alternatively, the combination used according to the first aspect may be a combination of XL228 and MK-2206. Alternatively, the combination used according to the first aspect may be a combination of BMS-536924 and afloresetin. Alternatively, the combination is brigatinib (IGF1R inhibitor) and MK-2206 (Akt inhibitor). Alternatively, the combination is linsitinib (IGF1R inhibitor) and patasertinib (Akt inhibitor). Alternatively, the combination is linsitinib (IGF1R inhibitor) and BAY1125976 (Akt inhibitor). Alternatively, the combination is linsitinib (IGF1R inhibitor) and capasertinib (Akt inhibitor). Alternatively, the combination is linsitinib (IGF1R inhibitor) and milansetinib (Akt inhibitor). Alternatively, the combination is XL228 (IGF1R inhibitor) and patasetinib (Akt inhibitor). Alternatively, the combination is GSK1904529A (IGF1R inhibitor) and patasetinib (Akt inhibitor). Alternatively, the combination is GSK1904529A (IGF1R inhibitor) and afloretinib (Akt inhibitor). Alternatively, the combination is linsitinib (IGF1R inhibitor) and afloretinib (Akt inhibitor). Alternatively, the combination is BMS-536924 (IGF1R inhibitor) and MK-2206 (Akt inhibitor). Alternatively, the combination is BMS-536924 (IGF1R inhibitor) and patasetinib (Akt inhibitor). Alternatively, the combination is BMS-536924 (IGF1R inhibitor) and milanthione (Akt inhibitor). Alternatively, the combination is BMS-536924 (IGF1R inhibitor) and capasitinib (Akt inhibitor). Alternatively, the combination is BMS-536924 (IGF1R inhibitor) and BAY1125976 (Akt inhibitor). Alternatively, the combination is GSK1904529A (IGF1R inhibitor) and milanthione (Akt inhibitor). Alternatively, the combination is GSK1904529A (IGF1R inhibitor) and capasitinib (Akt inhibitor). Alternatively, the combination is GSK1904529A (IGF1R inhibitor) and BAY1125976 (Akt inhibitor). Alternatively, the combination is AXL-1717 (IGF1R inhibitor) and MK-2206 (Akt inhibitor). Alternatively, the combination is AXL-1717 (IGF1R inhibitor) and aflusertib (Akt inhibitor). Alternatively, the combination is AXL-1717 (IGF1R inhibitor) and patasertib (Akt inhibitor).Alternatively, the combination is AXL-1717 (IGF1R inhibitor) and miracitinib (Akt inhibitor). Alternatively, the combination is AXL-1717 (IGF1R inhibitor) and capasitinib (Akt inhibitor). Alternatively, the combination is AXL-1717 (IGF1R inhibitor) and BAY1125976 (Akt inhibitor).

[0017] In some instances, the cancer is a KRAS mutant cancer.

[0018] In some cases, the cancer is an ARID1A mutant and / or an ARID2 mutant cancer. For example, the cancer can be an ARID1A mutant cancer. The cancer can be an ARID2 mutant cancer. The cancer can be an ARID1A mutant and an ARID2 mutant cancer.

[0019] In some cases, the cancer is an ARID1A mutant and / or an ARID2 mutant cancer, and is an IRS4 wild-type cancer. For example, the cancer can be an ARID1A mutant and an IRS4 wild-type cancer. The cancer can be an ARID2 mutant and an IRS4 wild-type cancer. The cancer can be an ARID1A mutant, an ARID2 mutant, and an IRS4 wild-type cancer.

[0020] In some cases, the cancer is ARID1A mutant and / or ARID2 mutant, and IRS4 wild-type colorectal cancer. In some cases, the cancer is ARID1A mutant and / or ARID2 mutant, and IRS4 wild-type colorectal cancer. And the IGF1R inhibitor is lincitinib, and the Akt inhibitor is MK-2206.

[0021] In some instances, the cancer is ARID1A mutant ovarian cancer. In some instances, the cancer is ARID1A mutant ovarian cancer, and the IGF1R inhibitor is lincitinib, and the Akt inhibitor is MK-2206.

[0022] In some instances, the cancer is ARID1A mutant endometrial cancer. In some instances, the cancer is ARID1A mutant endometrial cancer, and the IGF1R inhibitor is lincitinib, and the Akt inhibitor is MK-2206.

[0023] It will be appreciated that the IGF1R inhibitor and the Akt inhibitor may be administered together or separately, and may be administered simultaneously or at different times. For example, the compounds may be administered on different days as part of a treatment cycle or regimen. Suitably, but not necessarily, the IGF1R inhibitor and the Akt inhibitor are formulated separately. In a preferred method, both compounds are formulated for oral administration.

[0024] The claimed combination therapies may be used both curatively and palliatively. They may result in better patient outcomes and / or experiences compared to other treatment options, and additionally or alternatively, they may expand the treatment options available to patients.

[0025] Suitably, the patient may be a human patient.

[0026] The present invention also relates to a method of treating cancer in a patient in need thereof, wherein the method comprises the step of administering to the patient an effective amount of an IGF1R inhibitor in combination with an effective amount of an Akt inhibitor, wherein the cancer is selected from colorectal cancer, ovarian cancer and endometrial cancer.

[0027] The present invention also relates to a method of treating cancer in a patient in need thereof, wherein the method comprises the step of administering to the patient an effective amount of an IGF1R inhibitor in combination with an effective amount of an Akt inhibitor, wherein the cancer is selected from colorectal cancer, ovarian cancer and endometrial cancer.

[0028] The present invention also relates to a method of treating cancer in a patient in need thereof, wherein the method comprises the step of administering to the patient an effective amount of an Akt inhibitor in combination with an effective amount of an IGF1R inhibitor, wherein the cancer is selected from the group consisting of colorectal cancer, ovarian cancer, and endometrial cancer.

[0029] The present invention also relates to the use of a combination of an IGF1R inhibitor and an Akt inhibitor in the preparation of a medicament for treating cancer in a patient, wherein the cancer is selected from the group consisting of colorectal cancer, ovarian cancer and endometrial cancer.

[0030] The present invention also relates to the use of an IGF1R inhibitor in the preparation of a medicament for treating cancer in a patient in combination with an Akt inhibitor, wherein the cancer is selected from the group consisting of colorectal cancer, ovarian cancer and endometrial cancer.

[0031] The present invention also relates to the use of an Akt inhibitor in the preparation of a medicament for treating cancer in a patient in combination with an IGF1R inhibitor, wherein the cancer is selected from the group consisting of colorectal cancer, ovarian cancer and endometrial cancer.

[0032] The present invention includes any combination of the described aspects and preferred features unless such a combination is expressly impermissible or explicitly avoided. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Embodiments and experiments illustrating the principles of the present invention will now be discussed with reference to the accompanying drawings, in which:

[0034] Figure 1 : Correlation of individual biomarkers with synergy in response to MK-2206+linsitinib in colorectal cancer cell lines. Log2ΔIC 50( A) and ΔE max(B) Plotted against the mutation status of ARID1A. Each point is the average response of a single cell line. Box plots show median and interquartile range. WT: wild type; MUT: mutant. The dotted line represents the threshold, above which cell lines are defined as synergistic for the combination. See Example 2.

[0035] Figure 2 : Correlation of individual biomarkers with synergy in response to MK-2206+linsitinib in colorectal cancer cell lines. Log2ΔIC 50( A) and ΔE max (B) Plotted against the mutation status of ARID2. Each point is the average response of a single cell line. Box plots show median and interquartile range. WT: wild type; MUT: mutant. The dotted line represents the threshold, above which cell lines are defined as synergistic for the combination. See Example 2.

[0036] Figure 3 : Correlation of individual biomarkers with synergy in response to MK-2206+linsitinib in colorectal cancer cell lines. Log2ΔIC 50( A) and ΔE max (B) Plotted against the mutation status of IRS4. Each point is the average response of a single cell line. Box plots show median and interquartile range. WT: wild type; MUT: mutant. Dashed line represents the threshold above which cell lines are defined as synergistic for that combination. See Example 2.

[0037] Figure 4 : Correlation of mutation status of ARID1A, ARID2, and IRS4 and biomarker combinations with sensitivity to MK-2206 (anchor) + lincitinib (pool) in colon cancer cell lines. 50 The boxes below the graphs represent the mutant (dark grey or black) or wild type (light grey) states of the genes shown. Each point is the average response of a single cell line. See Example 2.

[0038] Figure 5:The mutation status of ARID1A, ARID2 and IRS4 in colon cancer cell lines and the correlation of biomarker combinations with sensitivity to MK-2206 (anchor) + linsitinib (library). The box plot shows the combined effects of biomarker ARID1A mutation and ARID2. The box plot marked with "ARID1A or ARID2" shows the effects of MK-2206 (anchor) + linsitinib (library) in colon cancer cell lines with ARID1A mutation or ARID2 mutation (including colon cancer cell lines with ARID1A mutation and ARID2 mutation). The box plot marked with "others" shows the effects of MK-2206 (anchor) + linsitinib (library) in all other colon cancer cell lines. Each point is the average response of a single cell line. A two-tailed Welch t test was performed. The box plot shows the median and interquartile range. The dotted line represents a threshold, and the cell lines above the threshold are defined as being synergistic for the combination. See Example 2.

[0039] Figure 6 :The mutation status of ARID1A, ARID2 and IRS4 in colon cancer cell lines and the correlation of biomarker combinations with sensitivity to MK-2206 (anchor) + linsitinib (library). The box plot shows the combined effects of biomarker ARID1A mutation, ARID2 mutation and IRS4 wild type. The box plot marked with "ARID1A / ARID2 / IRS4wt" shows the effects of MK-2206 (anchor) + linsitinib (library) in colon cancer cell lines with ARID1A mutation or ARID2 mutation combined with IRS4 wild type state (including colon cancer cell lines with ARID1A mutation and ARID2 mutation). The box plot marked with "other" shows the effects of MK-2206 (anchor) + linsitinib (library) in all other colon cancer cell lines. Each point is the average response of a single cell line. The box plot shows the median and interquartile range. The dotted line represents the threshold, and the cell lines above the threshold are defined as being synergistic for the combination. See Example 2.

[0040] Figure 7: Correlation of mutational status of ARID1A, ARID2, and IRS4 and biomarker combinations with sensitivity to other IGF1R and Akt inhibitor combinations in colon cancer cell lines. For each combination, an Akt inhibitor was combined with an IGF1R inhibitor over a discrete 1,000-fold (7-point) dose range in four colorectal cancer cell lines. Viability was measured after 72 hours of drug treatment using CellTiter-Glo reagent. Viability measurements for single agents and combinations were fitted per cell line, and multiple parameters were derived, including single agent values ​​and a range of synergy scores. For all concentration combination measurements, Bliss excess was calculated by comparing the observed combined response of the cells to the response predicted by the Bliss independence model based on monotherapy activity. The "Bliss window" is reported as the highest Bliss excess value measured in 25 possible 3×3 sub-matrices or "windows" in the 7×7 dose matrix. The Akt and IGF1R inhibitor combinations shown are: (A) BMS-536924 (IGF1R inhibitor) + aflumilast (Akt inhibitor); (B) GSK1904529A (IGF1R inhibitor) + aflumilast (Akt inhibitor); (C) GSK1904529A (IGF1R inhibitor) + patasertib (Akt inhibitor); (D) lincitinib (IGF1R inhibitor) + patasertib (Akt inhibitor); (E) XL228 (IGF1R inhibitor) + patasertib (Akt inhibitor) t inhibitor); (F) BMS-536924 (IGF1R inhibitor) + MK-2206 (Akt inhibitor); (G) brigatinib (IGF1R inhibitor) + MK-2206 (Akt inhibitor); (H) GSK1904529A (IGF1R inhibitor) + MK-2206 (Akt inhibitor); (I) linsitinib (IGF1R inhibitor) + MK-2206 (Akt inhibitor); and (J) XL228 (IGF1R inhibitor) + MK-2206 (Akt inhibitor). Box plots show the combined effects of biomarker ARID1A mutation, ARID2 mutation, and IRS4 wild-type. The box plots labeled "Biomarker +ve" show the effects of the labeled IGF1R and Akt inhibitor combination in colon cancer cell lines with ARID1A mutation or ARID2 mutation (including colon cancer cell lines with ARID1A mutation and ARID2 mutation) combined with IRS4 wild-type state. The box plots labeled "Biomarker -ve" are all other colon cancer cell lines. Each point is a replicate, and there are 5-8 replicates for each cell line. The box plots show the median and interquartile range. See Example 3.

[0041] Figure 8: Mutation status of ARID1A in ovarian and endometrial cancer cell lines and correlation with sensitivity to MK-2206+linsitinib. Selected ovarian (A) or endometrial (B) cancer cell lines were treated with MK-2206+linsitinib. Synergy measure ΔLog2 IC 50 and ΔE max Generated as described in Example 5. Graphs show two independent replicates for each cell line. DETAILED DESCRIPTION

[0042] Various aspects and embodiments of the present invention will now be discussed with reference to the accompanying drawings. Further aspects and embodiments will be apparent to those skilled in the art. All documents mentioned herein are incorporated herein by reference.

[0043] IGF1R inhibitors

[0044] The insulin-like growth factor 1 receptor (IGF1R or IGF-1R) is a tyrosine kinase receptor, i.e. it signals by causing the addition of a phosphate molecule on specific tyrosines. IGF1R is composed of two alpha subunits and two beta subunits. The IGF1R signaling pathway has been implicated in several cancers, as IGF1R is overexpressed in cancer cells, stimulates proliferation, enables oncogenic transformation, and inhibits apoptosis. It is believed that IGF1R has anti-apoptotic properties, which allow cancer cells to resist the cytotoxic effects of chemotherapeutic drugs or radiation therapy.

[0045] Suitably, the IGF1R inhibitor is selected from linsitinib, GSK1904529A, XL228, BMS-536924, BMS-754807, brigatinib, AXL-1717 and KW-2450; or it may be an IGF1R antibody. In some cases, the IGF1R inhibitor is selected from linsitinib, GSK1904529A, XL228, BMS-536924, BMS-754807, brigatinib, AXL-1717 and KW-2450. In some cases, the IGF1R inhibitor is selected from linsitinib, GSK1904529A, XL228, BMS-536924, BMS-754807, brigatinib and AXL-1717. In some cases, the IGF1R inhibitor is selected from linsitinib, GSK1904529A, XL228, BMS-536924 and brigatinib. In some cases, the IGF1R inhibitor is selected from linsitinib, GSK1904529A, XL228 and BMS-536924. In some cases, the IGF1R inhibitor is selected from linsitinib and GSK1904529A. Preferably, the IGF1R inhibitor is linsitinib.

[0046] Lincitinib

[0047] Lincitinib is also known as OSI-906. It is a selective inhibitor of insulin-like growth factor 1 receptor (IGF-1R or IGF1R) with an IC of 50 is 35nM. IGF1R is overexpressed in cancer cells, stimulates proliferation, achieves oncogenic transformation, and inhibits apoptosis. In other words, lincitinib is an IGF1Ri. It has the following structure:

[0048]

[0049] In IUPAC nomenclature, it may be referred to as 3-[8-amino-1-(2-phenyl-7-quinolyl)-3-imidazo[1,5-a]pyrazinyl]-1-methyl-1-cyclobutanol. It is commercially available.

[0050] Lincitinib is also a potent inhibitor of insulin receptor (IR) with an IC 50 Without wishing to be bound by any particular theory, the inventors postulate that the activity may be mediated by dual inhibition of these targets.

[0051] GSK1904529A

[0052] GSK1904529A is also known as GSK 4529. It is a selective inhibitor of IGF1R and IR with an IC of 50 27nM and 25nM respectively, and the selectivity for IGF1R / IR is >100-fold over Akt1 / 2, Aurora A / B, B-Raf, CDK2 and EGFR. It has the following structure:

[0053]

[0054] In IUPAC nomenclature, it may be referred to as N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonylpiperazin-1-yl)-1-piperidinyl]anilino]pyrimidin-4-yl]imidazo[1,2-a]pyridin-2-yl]-2-methoxybenzamide. It is commercially available.

[0055] XL228

[0056] XL228 is a protein kinase inhibitor with an IC of 1.1 for IGF1R in a cell-free assay. 50 In cell-free assays, XL228 also exhibited IC values ​​of 5 nM, 1.4 nM, 3.1 nM, 6.1 nM, and 2 nM for wild-type ABL kinase, ABL T315I, Aurora A, SRC, and LYN, respectively.50 . It has the following structure:

[0057]

[0058] In IUPAC nomenclature, it may be referred to as N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-isopropylisoxazol-5-yl)methyl]-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine. It is commercially available.

[0059] BMS-536924

[0060] BMS-536924 is also known as CS-0117. It is an ATP-competitive IGF1R / IR inhibitor with an IC 50 is 100nM / 73nM. It has an effect on Mek (IC 50 is 182nM), Fak (IC 50 150 nM) and Lck (IC 50 341nM) also has moderate activity and minimal activity against Akt1 and MAPK1 / 2. It has the following structure:

[0061]

[0062] In IUPAC nomenclature, it may be referred to as 4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-(4-methyl-6-morpholino-1H-benzimidazol-2-yl)-1H-pyridin-2-one. It is commercially available.

[0063] BMS-754807

[0064] BMS-754807 is a potent and reversible IGF1R / IR inhibitor with an IC of 50 is 1.8nM / 1.7nM. It has an inhibitory effect on Met (c-Met; IC 50 5.6nM), Aurora A / B (IC 50 9nM / 25nM), TrkA / B (IC 50 7.4nM / 4.1nM) and Ron (IC 50 44 nM) and showed weaker potency against Flt3 (IC 50 170nM), Lck, MK2, PKA, and PKC are almost inactive. It has the following structure:

[0065]

[0066] In IUPAC nomenclature, it may be referred to as 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-pyrrolidine-2-carboxamide. It is commercially available.

[0067] Brigatinib

[0068] Brigatinib is also known as AP26113. It is a potent and selective ALK (IC 50 0.6 nM) and ROS1 (IC 50 It also inhibits IGF1R (IC 50 24.9nM), IR (IC 50 196 nM) and FLT3 (IC 50 It has the following structure:

[0069]

[0070] In IUPAC nomenclature, it may be referred to as 5-chloro-N4-(2-dimethylphosphorylphenyl)-N2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)-1-piperidinyl]phenyl]pyrimidine-2,4-diamine. It is commercially available.

[0071] AXL-1717

[0072] AXL-1717 is also known as AXL1717, picropodophyllin or PPP. It is an IGF-1R inhibitor with an IC 50 1 nM. It exhibits selectivity for IGF-1R. That is, AXL-1717 is an IGF1Ri. It does not co-inhibit tyrosine phosphorylation of IR or a selected group of receptors that are less associated with IGF-IR (such as FGF-R, PDGF-R or EGF-R). AXL-1717, which has anti-tumor activity, induces apoptosis. It has the following structure:

[0073]

[0074] In IUPAC nomenclature, it may be referred to as (5R,5aR,8aS,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one. It is commercially available.

[0075] KW-2450

[0076] KW-2450 is an orally active multikinase inhibitor that inhibits both the insulin-like growth factor receptor (IGF-1R) and the insulin receptor (IR). 50 7.39nM and 5.64nM respectively. It has the following structure:

[0077]

[0078] In IUPAC nomenclature, it may be referred to as N-[5-[[4-(2-hydroxyacetyl)piperazin-1-yl]methyl]-2-[(E)-2-(1H-indazol-3-yl)vinyl]phenyl]-3-methylthiophene-2-carboxamide. It is commercially available.

[0079] IGF1R Antibody

[0080] Suitably, the IGF1R inhibitor may be an IGF1R antibody.The IGF1R antibody may be an IGF1R monoclonal antibody (mAb). The IGF1R antibody can be selected from the group consisting of tetoclax (Horizon Therapeutics USA Inc; Genmab AS; Horizon Therapeutics Plc; F. Hoffmann-La Roche Ltd), AVE-1642 (Viridian Therapeutics Inc; Zenas BioPharma (USA) LLC; ImmunoGen Inc), ganituzumab (Amgen Inc; Takeda Pharmaceutical Co Ltd), darototumumab (Merck & Co Inc), lonigutamab ugodotin (Acelyrin Inc), A-12 (University of Washington), VRDN-002 (Viridian Therapeutics Inc), VRDN-003 (Viridian Therapeutics Inc), ZB-011 (Zenas BioPharma (USA) LLC), BIIB-022 (Biogen Inc), citoclax (Eli Lilly and Co), phentoclax (Pfizer Inc), M-590 (University of Hong Kong Kong), rotuximab (Merck & Co Inc), XGFR-2 (F. Hoffmann-La Roche Ltd), XGFR-4 (F. Hoffmann-La Roche Ltd) and estuzumab (Merrimack Pharmaceuticals Inc).

[0081] Akt inhibitors

[0082] The Akt signaling pathway is associated with the inhibition of apoptosis and stimulation of cell proliferation following activation of Akt (also known as protein kinase B), a serine / threonine kinase. Currently, three mammalian isoforms are known: Akt1 / PKB-α, Akt2 / PKB-β, and Akt3 / PKB-γ.

[0083] Akt is targeted by both molecules that block its ATP binding site and by targeting so-called allosteric (other) sites (Lazaro et al. Biochem Soc Trans. 2020 Jun 30; 48(3):933-943; Kostaras et al. Br J Cancer. 2020 Aug; 123(4):542-555). While ATP-competitive Akt inhibitors (e.g. compounds such as capasitinib, aflorisertib, and patasertib) have predictable effects on Akt's ability to phosphorylate target proteins simply by blocking substrate access to the active site, allosteric Akt inhibitors generally have multiple and less predictable effects on enzyme function. MK-2206 (and other allosteric Akt inhibitors, such as miransertib and BAY1125976) bind to Akt at a site different from the active site of Akt, but still exert an inhibitory effect on Akt kinase activity. This effect may be due to conformational changes induced by compound binding. Such conformational changes may have additional effects on Akt activity, such as altering its ability to bind partner proteins. Thus, allosteric Akt inhibitors may exert additional effects on target proteins compared to active site blockade.

[0084] Thus, in some cases, the Akt inhibitor is an allosteric Akt inhibitor, such as MK-2206, miranthodei, and BAY1125976.

[0085] In other cases, the Akt inhibitor is an ATP-competitive Akt inhibitor, such as capasertib, aflorisertib, and patasertib.

[0086] Suitably, the Akt inhibitor is selected from MK-2206, capasitinib, patasert, afloresert, milanset, eupressor, triciribine, PTX-200, TAS-117, COTI-2, LY-2503029, MK-4440 and BAY1125976. In some cases, the Akt inhibitor is selected from MK-2206, capasitinib, patasert, afloresert, milanset and BAY1125976. In some cases, the Akt inhibitor is selected from MK-2206, capasitinib, milanset and BAY1125976. In some cases, the Akt inhibitor is selected from MK-2206, patasert and afloresert. Preferably, the Akt inhibitor is MK-2206.

[0087] MK-2206

[0088] MK-2206 is also known as UNII-51HZG6MP1K. It is a pan-Akt inhibitor with an IC of 2.1 for Akt1 / 2 / 3 in a cell-free assay. 508nM / 12nM / 65nM respectively, and have the following structure:

[0089]

[0090] In IUPAC nomenclature, it may be referred to as 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one. It is commercially available and is usually supplied and used as the dihydrochloride salt.

[0091] Capasitinib

[0092] Capasitinib, also known as AZD5363, potently inhibits all isoforms of Akt (Akt1 / Akt2 / Akt3), with an IC of 2.3 for Akt1 / 2 / 3 in a cell-free assay. 50 3nM / 8nM / 8nM respectively. It has the following structure:

[0093]

[0094] In IUPAC nomenclature, it may be referred to as 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide. It is commercially available.

[0095] Patasetti

[0096] Patasertib is also known as GDC-0068 and RG7440. It is a highly selective pan-Akt inhibitor with an IC of 2.1 for Akt1 / 2 / 3 in a cell-free assay. 50 5nM / 18nM / 8nM respectively. It has the following structure:

[0097]

[0098] In IUPAC nomenclature, it may be referred to as (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-(isopropylamino)propan-1-one. It is commercially available.

[0099] Afloxacin

[0100] Aflusertib is also known as GSK2110183 and ASB138. It is a potent, orally bioavailable Akt inhibitor that inhibits the K of Akt1 / 2 / 3 in a cell-free assay. i0.08nM / 2nM / 2.6nM respectively. It has the following structure:

[0101]

[0102] In IUPAC nomenclature, it can be referred to as N-[(1S)-1-(aminomethyl)-2-(3-fluorophenyl)ethyl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)thiophene-2-carboxamide. It is commercially available.

[0103] Milanseti

[0104] Miranthide, also known as ARQ-092, is a potent, selective, and orally bioavailable allosteric inhibitor of Akt with an IC of 1.1 for Akt1 / 2 / 3 in a cell-free assay. 50 2.7nM / 14nM / 8.1nM respectively. It has the following structure:

[0105]

[0106] In IUPAC nomenclature, it may be referred to as 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine. It is commercially available and is usually supplied and used as the hydrochloride salt.

[0107] Eupressant

[0108] Eupressant is also known as GSK2141795, GSK795, and UPB795. It is a selective, ATP-competitive, and orally bioavailable Akt inhibitor with an IC of 2.3 for Akt1 / 2 / 3 in a cell-free assay. 50 180nM / 328nM / 38nM respectively. It has the following structure:

[0109]

[0110] In IUPAC nomenclature, it may be referred to as N-[(2S)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide. It is commercially available.

[0111] Quxi Libin

[0112] Triciribine is also known as NSC 154020, VD-0002, vqd-002, API-2, and TCN. It is a DNA synthesis inhibitor but also inhibits Akt in the PC3 cell line (a human prostate cancer cell line) with an IC50 It has the following structure:

[0113]

[0114] In IUPAC nomenclature, it can be referred to as (2R,3R,4S,5R)-2-(5-amino-7-methyl-2,6,7,9,11-pentaazatricyclo[6.3.1.0 4,12 ] dodeca-1(12),3,5,8,10-pentaen-2-yl)-5-(hydroxymethyl)oxacyclopentane-3,4-diol. It is commercially available and can be supplied and used as the phosphate PTX-200 described below.

[0115] PTX-200

[0116] PTX-200 is also known as triciribine phosphate, tricycloside phosphate, and TCN-P. It is the phosphate salt of triciribine mentioned above, which inhibits Akt in PC3 cell line (human prostate cancer cell line), IC 50 It has the following structure:

[0117]

[0118] In IUPAC nomenclature, it can be referred to as [(2R,3S,4R,5R)-5-(5-amino-7-methyl-2,6,7,9,11-pentaazatricyclo[6.3.1.0 4,12

[0013]

[0014]

[0015]

[0016]

[0017]

[0018]

[0019]

[0020]

[0031]

[0032]

[0033]

[0034]

[0035]

[0036]

[0037]

[0038]

[0039]

[0040]

[0041]

[0042]

[0043]

[0044]

[0045]

[0046]

[0047]

[0048]

[0049]

[0050]

[0051]

[0052]

[0053]

[0054]

[0055]

[0056]

[0057]

[0058]

[0059]

[0061]

[0062]

[0063]

[0064]

[0065] [00

[0119] TAS-117

[0120] TAS-117 is a potent, selective, orally active allosteric Akt inhibitor with IC 50 4.8nM / 1.6nM / 44nM respectively. TAS-117 triggers anti-myeloma activity and enhances severe endoplasmic reticulum (ER) stress induced by proteasome inhibition. TAS-117 induces apoptosis and autophagy. It has the following structure:

[0121]

[0122] In IUPAC nomenclature, it can be referred to as 3-amino-1-methyl-3-[4-(5-phenyl-8-oxa-3,6,12-triazatricyclo[7.4.0.0 2,6 ]tridec-1(9),2,4,10,12-pentaen-4-yl)phenyl]cyclobutane-1-ol. It is commercially available and can be supplied and used as the hydrochloride salt.

[0123] COTI-2

[0124] COTI-2 is an anticancer drug with low toxicity. It is an orally available third-generation thiosemicarbazone and activator of mutant forms of p53 protein with potential antitumor activity. COTI-2 works by both reactivating mutant p53 and inhibiting the PI3K / Akt / mTOR pathway. COTI-2 induces apoptosis in a variety of human tumor cell lines. COTI-2 exhibits antitumor activity in HNSCC through p53-dependent and p53-independent mechanisms. COTI-2 converts mutant p53 to wild-type conformation. It has the following structure:

[0125]

[0126] In IUPAC nomenclature, it may be referred to as N-[(Z)-6,7-dihydro-5H-quinolin-8-ylideneamino]-4-pyridin-2-ylpiperazine-1-carbothioamide. It is commercially available.

[0127] LY-2503029

[0128] LY-2503029 (Eli Lilly and Co) is a protein kinase B (Akt) inhibitor. LY-2503029 binds to and inhibits the activity of Akt, resulting in the inhibition of the PI3K / Akt signaling pathway that causes tumor cell proliferation and the induction of tumor cell apoptosis.

[0129] MK-4440

[0130] MK-4440 (Merck & Co Inc) is also known as MK4440, ARQ 751 and vevorisertib. It is an orally active, potent and selective pan-AKT serine / threonine kinase inhibitor with an IC of 1. 50 0.55nM / 0.81nM / 1.31nM respectively. It is being developed for the treatment of cancer. In particular, MK-4440 as a single agent or in combination with other anticancer agents can be used to study solid tumors with PIK3CA / Akt / PTEN mutations. It has the following structure:

[0131]

[0132] In IUPAC nomenclature, it may be referred to as N-[1-[3-[3-[4-(1-aminocyclobutyl)phenyl]-2-(2-aminopyridin-3-yl)imidazo[4,5-b]pyridin-5-yl]phenyl]piperidin-4-yl]-N-methylacetamide. It is commercially available.

[0133] BAY1125976

[0134] BAY1125976 is a selective allosteric Akt1 / Akt2 inhibitor. It inhibits Akt1 and Akt2 activity with an IC of 50 The values ​​are 5.2nM and 18nM respectively. It has the following structure:

[0135]

[0136] In IUPAC nomenclature, it may be referred to as 2-[4-(1-aminocyclobutyl)phenyl]-3-phenylimidazo[1,2-b]pyridazine-6-carboxamide. It is commercially available.

[0137] Specific IGF1R and Akt inhibitor combinations

[0138] In some cases, the combination of an IGF1R inhibitor and an Akt inhibitor used in the treatment methods described herein can be a specific IGF1R inhibitor and Akt inhibitor combination.

[0139] In some cases, the combination can be selected from: linsitinib (IGF1R inhibitor) and MK-2206 (Akt inhibitor); BMS-754807 (IGF1R inhibitor) and MK-2206 (Akt inhibitor); GSK1904529A (IGF1R inhibitor) and MK-2206 (Akt inhibitor); XL228 (IGF1R inhibitor) and MK-2206 (Akt inhibitor); BMS-536924 (IGF1R inhibitor) and aflotoxin (Akt inhibitor); BMS-536924 (IGF1R inhibitor) and MK-2206 (Akt inhibitor); brigatinib (IGF1R inhibitor) and M K-2206 (Akt inhibitor); lincitinib (IGF1R inhibitor) and patacetyl (Akt inhibitor); lincitinib (IGF1R inhibitor) and BAY1125976 (Akt inhibitor); lincitinib (IGF1R inhibitor) and capasitinib (Akt inhibitor); lincitinib (IGF1R inhibitor) and miracetyl (Akt inhibitor); XL228 (IGF1R inhibitor) and patacetyl (Akt inhibitor); GSK1904529A (IGF1R inhibitor) and patacetyl (Akt inhibitor); GSK1904529A (IGF1R inhibitor) and afloresert (Akt inhibitor); lincitinib (IGF1R inhibitor) and capasitinib (Akt inhibitor); 1R inhibitor) and afloridesertib (Akt inhibitor); BMS-536924 (IGF1R inhibitor) and patasertib (Akt inhibitor); BMS-536924 (IGF1R inhibitor) and miracetitide (Akt inhibitor); BMS-536924 (IGF1R inhibitor) and capasertib (Akt inhibitor); BMS-536924 (IGF1R inhibitor) and BAY1125976 (Akt inhibitor); GSK1904529A (IGF1R inhibitor) and miracetitide (Akt inhibitor); GSK1904529A (IGF1R inhibitor) and capasertib (Akt inhibitor); GSK19 04529A (IGF1R inhibitor) and BAY1125976 (Akt inhibitor); AXL-1717 (IGF1R inhibitor) and MK-2206 (Akt inhibitor); AXL-1717 (IGF1R inhibitor) and aflorisertib (Akt inhibitor); AXL-1717 (IGF1R inhibitor) and patasertib (Akt inhibitor); AXL-1717 (IGF1R inhibitor) and miracetam (Akt inhibitor); AXL-1717 (IGF1R inhibitor) and capasertib (Akt inhibitor); and AXL-1717 (IGF1R inhibitor) and BAY1125976 (Akt inhibitor).

[0140] In some cases, the combination can be selected from: linsitinib (IGF1R inhibitor) and MK-2206 (Akt inhibitor); BMS-754807 (IGF1R inhibitor) and MK-2206 (Akt inhibitor); GSK1904529A (IGF1R inhibitor) and MK-2206 (Akt inhibitor); XL228 (IGF1R inhibitor) and MK-2206 (Akt inhibitor); BMS-536924 (IGF1R inhibitor) and aflotoxin (Akt inhibitor); BMS-536924 (IGF1R inhibitor) and MK-2206 (Akt inhibitor); brigatinib (IGF1R inhibitor) and MK-2206 (Akt inhibitor); lincitinib (IGF1R inhibitor) and patacetyl (Akt inhibitor); lincitinib (IGF1R inhibitor) and BAY1125976 (Akt inhibitor); lincitinib (IGF1R inhibitor) and capasertib (Akt inhibitor); lincitinib (IGF1R inhibitor) and miracetyl (Akt inhibitor); XL228 (IGF1R inhibitor) and patacetyl (Akt inhibitor); GSK1904529A (IGF1R inhibitor) and patacetyl (Akt inhibitor); and GSK1904529A (IGF1R inhibitor) and afloresertib (Akt inhibitor).

[0141] In some cases, the combination can be selected from: lincitinib (IGF1R inhibitor) and MK-2206 (Akt inhibitor); GSK1904529A (IGF1R inhibitor) and MK-2206 (Akt inhibitor); XL228 (IGF1R inhibitor) and MK-2206 (Akt inhibitor); BMS-536924 (IGF1R inhibitor) and MK-2206 (Akt inhibitor); BMS-536924 (IGF1R inhibitor) and Akt inhibitor. Flurisertib (Akt inhibitor); brigatinib (IGF1R inhibitor) and MK-2206 (Akt inhibitor); lincitinib (IGF1R inhibitor) and patasertib (Akt inhibitor); XL228 (IGF1R inhibitor) and patasertib (Akt inhibitor); GSK1904529A (IGF1R inhibitor) and patasertib (Akt inhibitor); and GSK1904529A (IGF1R inhibitor) and aflurisertib (Akt inhibitor).

[0142] In some cases, the combination can be selected from: lincitinib (IGF1R inhibitor) and MK-2206 (Akt inhibitor); BMS-754807 (IGF1R inhibitor) and MK-2206 (Akt inhibitor); and GSK1904529A (IGF1R inhibitor) and MK-2206 (Akt inhibitor).

[0143] In some cases, the combination can be selected from: linsitinib (IGF1R inhibitor) and MK-2206 (Akt inhibitor); linsitinib (IGF1R inhibitor) and BAY1125976 (Akt inhibitor); linsitinib (IGF1R inhibitor) and capasitinib (Akt inhibitor); and linsitinib (IGF1R inhibitor) and miracetam (Akt inhibitor).

[0144] In some cases, the combination is lincitinib (IGF1R inhibitor) and MK-2206 (Akt inhibitor). In some cases, the combination is BMS-754807 (IGF1R inhibitor) and MK-2206 (Akt inhibitor). In some cases, the combination is GSK1904529A (IGF1R inhibitor) and MK-2206 (Akt inhibitor). In some cases, the combination is XL228 (IGF1R inhibitor) and MK-2206 (Akt inhibitor). In some cases, the combination is BMS-536924 (IGF1R inhibitor) and aflotoxin (Akt inhibitor). In some cases, the combination is BMS-536924 (IGF1R inhibitor) and MK-2206 (Akt inhibitor). In some cases, the combination is brigatinib (IGF1R inhibitor) and MK-2206 (Akt inhibitor). In some cases, the combination is linsitinib (IGF1R inhibitor) and patasetinib (Akt inhibitor). In some cases, the combination is linsitinib (IGF1R inhibitor) and BAY1125976 (Akt inhibitor). In some cases, the combination is linsitinib (IGF1R inhibitor) and capasitinib (Akt inhibitor). In some cases, the combination is linsitinib (IGF1R inhibitor) and milansetinib (Akt inhibitor). In some cases, the combination is XL228 (IGF1R inhibitor) and patasetinib (Akt inhibitor). In some cases, the combination is GSK1904529A (IGF1R inhibitor) and patasetinib (Akt inhibitor). In some cases, the combination is GSK1904529A (IGF1R inhibitor) and aflosetinib (Akt inhibitor). In some cases, the combination is linsitinib (IGF1R inhibitor) and afloretinib (Akt inhibitor). In some cases, the combination is BMS-536924 (IGF1R inhibitor) and patasertib (Akt inhibitor). In some cases, the combination is BMS-536924 (IGF1R inhibitor) and milansetib (Akt inhibitor). In some cases, the combination is BMS-536924 (IGF1R inhibitor) and capasertib (Akt inhibitor). In some cases, the combination is BMS-536924 (IGF1R inhibitor) and capasertib (Akt inhibitor). In some cases, the combination is BMS-536924 (IGF1R inhibitor) and BAY1125976 (Akt inhibitor). In some cases, the combination is GSK1904529A (IGF1R inhibitor) and milansetib (Akt inhibitor). In some cases, the combination is GSK1904529A (IGF1R inhibitor) and capasertib (Akt inhibitor). In some instances, the combination is GSK1904529A (IGF1R inhibitor) and BAY1125976 (Akt inhibitor).In some cases, the combination is AXL-1717 (IGF1R inhibitor) and MK-2206 (Akt inhibitor). In some cases, the combination is AXL-1717 (IGF1R inhibitor) and aflusertib (Akt inhibitor). In some cases, the combination is AXL-1717 (IGF1R inhibitor) and patasertib (Akt inhibitor). In some cases, the combination is AXL-1717 (IGF1R inhibitor) and milansetib (Akt inhibitor). In some cases, the combination is AXL-1717 (IGF1R inhibitor) and capasertib (Akt inhibitor). In some cases, the combination is AXL-1717 (IGF1R inhibitor) and BAY1125976 (Akt inhibitor).

[0145] Thus, the combination for use in the methods of treatment described herein may be a combination of lincitinib and MK-2206.

[0146] Pharmaceutically acceptable salts

[0147] As described herein, any compound may be provided as a pharmaceutically acceptable salt, hydrate or solvate. Suitable pharmaceutically acceptable salts are known in the art and are described, for example, in Berge et al., J Pharm Sci, 1977 66(1) p 1.

[0148] Application of active ingredients

[0149] The compound used in the method of the present invention can be administered by any suitable route, including oral and intravenous routes. It should be understood that oral administration may be preferred. The compound can be provided as a pharmaceutical composition comprising the compound and one or more pharmaceutically acceptable excipients. The preparation for oral administration can be in the form of a tablet or a capsule comprising a powder or a liquid.

[0150] Administration is preferably a "therapeutically effective amount" or "effective amount" (used interchangeably), which is sufficient to show benefit to an individual. The actual amount administered, as well as the rate and time course of administration, will depend on the nature and severity of the disease being treated. The prescription of treatment, such as dosage decisions, etc., is within the responsibility of general practitioners and other medical practitioners, and generally takes into account the condition to be treated, the condition of the individual patient, the site of administration, the method of administration, and other factors known to the physician. Examples of the above-mentioned techniques and regimens can be found in Remington's Pharmaceutical Sciences, 20th edition, 2000, pub. Lippincott, Williams & Wilkins.

[0151] Suitable dosing regimens may be based on those previously used in clinical trials and / or approved regimens.

[0152] For example, during a phase I clinical trial, linsitinib as a single agent was previously administered orally to patients at a dose of 150 mg twice daily (Fassnacht et al., Lancet Oncol., April 2015; 16(4): 426-435). The recommended dose of linsitinib for the phase II trial is 150 mg twice daily (Puzanov et al., Clin Cancer Res., February 15, 2015; 21(4): 701-711). Linsitinib is also administered in combination with irinotecan (which is a TOP1 inhibitor; Davis et al., Oncologist, December 2018; 23(12): 1409-e140) at a daily dose of 400-450 mg, with treatment administered in cycles, with linsitinib administered on days 1-3 every 7 days.

[0153] In patients with Ph+ leukemias that contain a T315I mutation or are resistant or intolerant to at least two previous BCR-ABL inhibitor therapies, XL228 is administered as a one-hour IV infusion once or twice a week. The dose levels tested so far are 0.45, 0.9, 1.8, 3.6, 7.2, and 10.8 mg / kg once a week and 3.6 mg / kg twice a week (https: / / ir.exelixis.com / news-releases / news-release-details / exelixis-reports-positive-phase-1-data-xl228-ash-annual-meeting). XL228 is also administered as a weekly 1-hour IV infusion at a maximum tolerated dose (MTD) of 6.5 mg / kg in patients with solid tumors or multiple myeloma (Smith et al., Journal of Clinical Oncology 2010 28:15_suppl, 3105-3105).

[0154] In a Phase II study, brigatinib was administered to patients with ALK-positive advanced non-small cell lung cancer at 180 mg once daily (QD), followed by 90 mg QD for 7 days until they experienced objective disease progression according to the response evaluation criteria for solid tumors. After radiological progression, patients who received brigatinib 180 mg QD and experienced no more than grade 2 toxicity during treatment could choose to increase the dose of brigatinib to 240 mg QD at the discretion of the investigator (Kim et al., Future Oncology 2021 17:14, 1709-1719).

[0155] AXL-1717 was administered at a dose of 300 or 400 mg AXL-1717 as a twice daily (BID) treatment in patients with previously treated locally advanced or metastatic non-small cell lung cancer (58 patients) (Bergqvist et al., Acta Oncologica, 56:3, 441-447, DOI: 10.1080 / 0284186X.2016.1253866).

[0156] In a Phase I study, KW-2450 was combined with lapatinib (a dual tyrosine kinase inhibitor) and letrozole (an aromatase inhibitor) at a dose of KW-2450 25 mg / day plus lapatinib 1500 mg / day and letrozole 2.5 mg / day in patients with advanced / metastatic hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer (Umehara et al. Therapeutic Advances in Medical Oncology. 2018; 10. Doi: 10.1177 / 1758835918786858).

[0157] MK-2206 was administered to patients at doses of 30 mg, 60 mg, 75 mg, and 90 mg every other day (Yap et al., J Clin Oncol., Dec 10, 2011; 29(35):4688-4695). Another trial gave patients 200 mg of MK-2206 once a week (Xing et al., Breast Cancer Res., Jul 5, 2019; 21(1):78). MK-2206 was also combined with selumetinib (a protein kinase inhibitor; Chung et al., JAMA Oncol., Apr 1, 2017; 3(4):516-522) and administered orally once a week at a dose of 135 mg.

[0158] Capasitinib was administered in a Phase III double-blind randomized study evaluating the efficacy of capasitinib and fulvestrant (a hormone therapy drug) in the treatment of patients with locally advanced (inoperable) or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+ / HER2-) breast cancer after recurrence or progression during or after aromatase inhibitor (AI) therapy. Capasitinib was administered at 400 mg (2 oral tablets) BID in an intermittent weekly dosing schedule, with dosing on days 1 to 4 of each week of a 28-day treatment cycle. (https: / / clinicaltrials.gov / ct2 / show / NCT04305496). In a phase II trial, capasitinib was also administered orally at 320 mg twice daily on a 4-day on / 3-day off schedule starting on day 2 of each 21-day cycle in patients with castration-resistant prostate cancer (Crabb et al., J Clin Oncol. 2021 Jan 20;39(3):190–201).

[0159] In a Phase II clinical trial, patasertib was administered with paclitaxel, a chemotherapy drug, at 400 mg once daily on days 1-21 of a 28-day cycle in patients with cancers with a high incidence of PI3K / Akt pathway activation, including triple-negative breast cancer (TNBC) (Kim et al., The Lancet Oncology, Vol. 18, No. 10, 2017, pp. 1360-1372; and Oliveira et al., Ann Oncol, Aug 1, 2019; 30(8):1289-1297. Doi: 10.1093 / annonc / mdz177).

[0160] In a phase IB dose escalation and expansion study, aflozumab was administered with carboplatin (a chemotherapy drug) and paclitaxel (another chemotherapy drug) using continuous oral doses of 50-150 mg aflozumab daily in patients with recurrent platinum-resistant ovarian cancer (Blagden et al., Clin Cancer Res (2019) 25(5): 1472–1478). In a phase I study, aflozumab was also administered at 25-150 mg daily in patients with multiple myeloma to assess the maximum tolerated dose (MTD), with a maximum tolerated dose of 125 mg daily observed (Spencer et al., Blood (2014) 124(14): 2190–2195).

[0161] In a phase IB study, mirathite was combined with anastrozole (a hormone therapy) at a dose of 200 mg QD, 5 days on / 9 days off, or 150 mg QD, 5 days on / 9 days off, in patients with PIK3CA and Akt1 mutant ER+ endometrial and ovarian cancer (Hyman et al., Cancer Res (2018) 78(13_Supplement): CT035; https: / / doi.org / 10.1158 / 1538-7445.AM2018-CT035). Mirathite was also taken orally daily at 10 mg (approximately 5 mg / m 2 / day), and then gradually increased to 30 mg per day (about 15 mg / m 2 / day), and then gradually increased to 50 mg per day (about 25 mg / m 2 / day) in patients with Proteus syndrome (Biesecker et al., Cold Spring Harb Mol Case Study, 2020 Feb 3;6(1):a004549; doi:10.1101 / mcs.a004549). A phase I study in hematologic malignancies also used 15 mg / m 2 QD, followed by a maximum dose increase to 25 mg / m 2 Give miracillin (https: / / www.drugdiscoverytrends.com / arqule-reports-positive-phase-i-data-in-haematological-malignancies-study / ).

[0162] In a phase I dose-escalation trial, eupressant was combined with trametinib (MEK1 / MEK2 inhibitor) at 50 mg QD in patients with solid tumors that may be sensitive to MEK and / or Akt inhibition (Tolcher et al., Cancer Chemother Pharmacol, April 2020; 85(4): 673-683). Eupressant was also combined with dabrafenib (an anticancer drug, B-Raf inhibitor) and trametinib (MEK1 / MEK2 inhibitor) at a dose of up to 75 mg once daily in patients with stage IIIC-IV BRAF mutant cancer orally (https: / / clinicaltrials.gov / ct2 / show / NCT01902173).

[0163] In a Phase 2a study, PTX-200 was administered at 35 mg weekly with 80 mg of paclitaxel in patients with locally advanced HER2-negative breast cancer (https: / / smallcaps.com.au / prescient-therapeutics-encouraging-efficacy-results-leading-cancer-drug-candidate-ptx-200 / ). PTX-200 was also administered at 25-55 mg / m when combined with cytarabine, a chemotherapy agent. 2 The dose (reduced to 15 mg / m if necessary) 2 ) administered intravenously within 1 hour in patients with relapsed or refractory acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), or chronic myeloid leukemia (CML) (https: / / clinicaltrials.gov / ct2 / show / study / NCT02930109).

[0164] In a phase 1b / 2a trial, COTI-2 was compared with 60 mg / m every 3 weeks 2 IV doses of cisplatin combination, administered orally at doses of 0.5-3.5 mg / kg 5 days per week in patients with solid tumors of ovarian, fallopian tube, primary peritoneal, endometrial, cervical, lung, pancreatic, or colorectal cancers, or head and neck squamous cell carcinomas (https: / / www.globenewswire.com / en / news-release / 2019 / 05 / 08 / 1819580 / 0 / en / Cotinga-Pharmaceuticals-Releases-Early-Interim-Data-of-Phase-1b-2a-Combination-Trial-of-COTI-2-in-Solid-Tumors.html).

[0165] In a phase I study, BAY1125976 was administered at 60 mg BID in patients with hormone receptor-positive metastatic breast cancer (including 9 patients with AKT1 E17K The method was orally administered to patients with HER2 mutations (Schneeweiss et al., Cancers 2019, 11(12), 1987; https: / / doi.org / 10.3390 / cancers11121987).

[0166] Suitable dosing regimens for other IGF1R inhibitors such as GSK1904529A, BMS-536924, and BMS-754807, and Akt inhibitors such as TAS-117, LY-2503029, and MK-4440 are also described in the art.

[0167] Thus, the active ingredients described herein may be administered in a dosage of about 1 mg to about 1000 mg, such as about 5 mg to about 700 mg, such as about 10 mg to about 500 mg. The dosage may depend on the dosing regimen.

[0168] In some embodiments, each dose of the IGF1R inhibitor can be administered at a dose of about 1 mg to about 1000 mg, such as about 50 mg to about 600 mg, such as about 100 mg to about 500 mg, such as about 150 mg to about 450 mg. In some embodiments, the IGF1R inhibitor can be administered at a dose of about 150 mg. The IGF1R inhibitor administered at the above doses can be selected from lincitinib, GSK1904529A, XL228, BMS-536924, BMS-754807, AXL-1717 and KW-2450 as described herein; or an IGF1R antibody.

[0169] In some embodiments, each dose of the Akt inhibitor can be administered at a dose of about 1 mg to about 1000 mg, such as about 10 mg to about 500 mg, such as about 30 mg to about 300 mg, such as about 60 mg to about 200 mg. The Akt inhibitor administered at the above dose can be selected from MK-2206, capasitinib, patasertib, aflorisertib, miransetib, eupsitib, triciribine, PTX-200, TAS-117, COTI-2, LY-2503029, MK-4440 and BAY1125976 as described herein.

[0170] When administered in combination, the active ingredients described herein can be administered simultaneously or sequentially. In some embodiments of the combination therapies described herein, the IGF1R inhibitor and the Akt inhibitor are administered sequentially. In some embodiments, the active ingredients are administered in a concurrent treatment cycle or regimen, and therefore only one of the agents is administered on some days.

[0171] Each active ingredient described herein may independently be administered orally or parenterally.

[0172] In some embodiments, the IGR1R inhibitor can be administered orally. For example, an IGF1R inhibitor, such as linsitinib, GSK1904529A, XL228, BMS-536924, BMS-754807, brigatinib, AXL-1717, or KW-2450, can be administered orally.

[0173] In some embodiments, linsitinib can be administered orally. In some embodiments, GSK1904529A can be administered orally. In some embodiments, XL228 can be administered orally. In some embodiments, BMS-536924 can be administered orally. In some embodiments, BMS-754807 can be administered orally. In some embodiments, brigatinib can be administered orally. In some embodiments, AXL-1717 can be administered orally. In some embodiments, KW-2450 can be administered orally.

[0174] In some embodiments, the Akt inhibitor can be administered orally. For example, an Akt inhibitor, such as MK-2206, capasertib, patasertib, aflorasertib, miranasertib, eupsitib, triciribine, PTX-200, TAS-117, COTI-2, LY-2503029, MK-4440, or BAY1125976, can be administered orally.

[0175] In some embodiments, MK-2206 can be administered orally. In some embodiments, capasertib can be administered orally. In some embodiments, patasertib can be administered orally. In some embodiments, afloresertib can be administered orally. In some embodiments, milansetib can be administered orally. In some embodiments, eupressertib can be administered orally. In some embodiments, triciribine can be administered orally. In some embodiments, PTX-200 can be administered orally. In some embodiments, TAS-117 can be administered orally. In some embodiments, COTI-2 can be administered orally. In some embodiments, LY-2503029 can be administered orally. In some embodiments, MK-4440 can be administered orally. In some embodiments, BAY1125976 can be administered orally.

[0176] Each active ingredient described herein can be independently administered daily, such as once a day (QD), twice a day (BID), three times a day (TID) or four times a day (QID), or can be administered less frequently, such as every other day or on certain days within a 7-day or 21-day cycle. Such treatment cycles are often used in chemotherapy treatments.

[0177] Suitably, the patient may be a human patient.

[0178] Cancer Type

[0179] The present invention relates to methods for treating cancer in patients, and in particular to treating intestinal (colorectal) cancer, ovarian cancer and / or endometrial cancer. Thus, in some aspects, the present invention relates to treating colon cancer (or colorectal cancer) in patients. Alternatively, in some aspects, the present invention relates to treating ovarian cancer in patients. Alternatively, in some aspects, the present invention relates to treating endometrial cancer in patients.

[0180] Preferably, the cancer is colorectal cancer.

[0181] In some aspects of the invention, the cancer may be a KRAS mutant cancer. In aspects of the invention where the cancer is colorectal cancer, the colorectal cancer may be a KRAS mutant colorectal cancer. In aspects of the invention where the cancer is ovarian cancer, the ovarian cancer may be a KRAS mutant ovarian cancer. In aspects of the invention where the cancer is endometrial cancer, the endometrial cancer may be a KRAS mutant endometrial cancer.

[0182] In some aspects of the invention, the cancer may be an ARID1A mutant and / or an ARID2 mutant cancer, and optionally may be an IRS4 wild-type cancer. In aspects of the invention in which the cancer is colorectal cancer, the colorectal cancer may be an ARID1A mutant and / or an ARID2 mutant colorectal cancer, and optionally may be an IRS4 wild-type colorectal cancer. In aspects of the invention in which the cancer is ovarian cancer, the ovarian cancer may be an ARID1A mutant and / or an ARID2 mutant ovarian cancer, and optionally may be an IRS4 wild-type ovarian cancer. In aspects of the invention in which the cancer is endometrial cancer, the endometrial cancer may be an ARID1A mutant and / or an ARID2 mutant endometrial cancer, and optionally may be an IRS4 wild-type endometrial cancer.

[0183] KRAS mutations

[0184] Suitably, in some aspects of the invention, the cancer is a KRAS mutant cancer. In some aspects of the invention wherein the cancer is colorectal cancer, the colorectal cancer is a KRAS mutant colorectal cancer. In some aspects of the invention wherein the cancer is ovarian cancer, the ovarian cancer is a KRAS mutant ovarian cancer. In some aspects of the invention wherein the cancer is endometrial cancer, the endometrial cancer is a KRAS mutant endometrial cancer.

[0185] In other words, by genomic analysis, the tumor was classified as having a KRAS mutation. The KRAS (Kirsten rat sarcoma virus) gene is an oncogene. The HUGO Gene Nomenclature Committee's symbol report for KRAS can be found at www.genenames.org, providing a link to its nucleotide sequence.

[0186] KRAS mutations are thought to be associated with approximately 40% of colorectal cancers and can be determined by tests known in the art. Most methods involve using PCR to amplify the appropriate region of the KRAS gene, including exons 2 and 3, and then using different methods to distinguish wild-type from mutant sequences in key codons (such as 12, 13, and 61). Detection methods include nucleic acid sequencing, allele-specific PCR methods, single-strand conformation polymorphism analysis, melting curve analysis, and probe hybridization. Tests for detecting KRAS mutations, such as The KRAS Mutation Test (Roche) and Therascreen KRASRGQ PCR Kit (Qiagen) are both FDA-approved (https: / / www.fda.gov / medical-devices / in-vitro-diagnostics / list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools).

[0187] In other words, a KRAS mutant cancer is a cancer that includes cells that have or carry an activating KRAS mutation. It will be appreciated that patients with colorectal cancer now routinely undergo KRAS mutation analysis.

[0188] As can be seen from Example 1, the inventors observed the desired potency and efficacy of the claimed combination in colorectal cancer cells, and in particular in the KRAS mutant patient population.

[0189] ARID1A and ARID2

[0190] The AT-rich interaction domain (ARID) family belongs to the superfamily of switch / sucrose non-fermentation (SWI / SNF) chromatin remodeling complexes, which are subfamily of ATP-dependent chromatin remodeling complexes found in eukaryotes (Zhu et al., Cancer Biology & Therapy, 2022, Vol. 23, No. 1, 104-111). The ARID family consists of a series of members related to the basic processes of cell function (including modification of chromatin structure and regulation of targeted gene transcription). All ARID family members contain a DNA binding domain, through which they can bind to targeted DNA and participate in the process of DNA replication, gene expression and cell growth, differentiation and development.

[0191] AT-rich interaction domain 1A (ARID1A, sometimes called BAF250a) is a non-catalytic DNA-binding subunit of the human SWI / SNF complex (chromatin remodeling complex) (Tessiri et al., Peer J, 2022, 10: e12750; Mullen et al., Cancer Treatment Reviews, 2021, 100, 102287). It is thought to play an important role in key cellular processes, including transcription, DNA replication, and DNA damage repair. A review by Mittal et al. (Mittal et al., 2020, Nat Rev Clin Oncol., July 17, 2020 (7): 435-448) cites papers showing that ATP-dependent chromatin remodeling factor SMARCA4 (also known as transcription activator BRG1) and ARID1A are recruited to DNA damage sites and assist in homologous recombination (HR)-mediated DNA repair and non-homologous end joining (NHEJ). ARID1A is also thought to interact with the DNA mismatch repair protein Msh2 (MutS homolog 2 or MSH2).

[0192] Mutations in ARID1A induce altered expression of multiple genes that contribute to carcinogenesis (e.g., cyclin-dependent kinase inhibitor 1A (CDKN1A), mothers against decapentaplegic homolog 3 (SMAD family member 3 or SMAD3), DNA mismatch repair protein Mlh1 (MutL protein homolog 1 or MLH1), and phosphoinositide-3-kinase interacting protein 1 (PIK3IP1)) through chromatin remodeling dysfunction, and have been shown to cause transformation of cells associated with the phosphoinositide 3-kinase (PI3K) / protein kinase B (PKB or Akt) pathway (i.e., PI3K / Akt pathway) (Takeda et al., Oncology Reports, 2016, 35:607-613). Mutations in ARID1A may impair DNA mismatch repair, leading to increased tumor mutational burden (TMB), programmed death-ligand 1 (PD-L1) expression, cytotoxic T lymphocyte (CTL) infiltration, and increased sensitivity to checkpoint inhibitors. For example, ARID1A mutations are associated with sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors (i.e., PARPi) and ataxia telangiectasia and Rad3-related protein (ATR) inhibitors (i.e., ATRi).

[0193] ARID1A is a frequently mutated tumor suppressor. Mutations in ARID1A are associated with a variety of cancers, such as ovarian clear cell carcinoma (Mittal et al., 2020, Nat Rev Clin Oncol., July 17, 2020 (7): 435-448), endometriosis-associated ovarian cancer (Samartzis et al., Int. J. Mol. Sci., 2013, 14, 188824-18849), endometrial cancer (Takeda et al., Oncology Reports, 2016, 35: 607-613) and cholangiocarcinoma (also known as cholangiocarcinoma; via activation of the PI3K / Akt pathway; Tessiri et al., Peer J, 2022, 10: e12750). Specifically, ARID1A is mutated in 9% of colorectal cancers (Mullen et al., Cancer Treatment Reviews, 2021, 100, 102287), and ARID1A is mutated in more than 50% of all ovarian clear cell carcinomas and ovarian endometrial carcinomas. ARID1A mutant breast and endometrial cancers are associated with increased PI-3K and Akt signaling and sensitivity to PI-3K and Akt inhibitors (Takeda et al., Oncology Reports, 2016, 35: 607-613). ARID1A alterations have been reported to co-occur with PI3K / Akt pathway activation in ovarian clear cell carcinoma, breast cancer, and gastric cancer (Huang et al. Mod Pathol. 2014 Jul;27(7):983-90; Samartzis et al. Oncotarget. 2014 Jul 30;5(14):5295-303; Zhang et al. Oncotarget. 2016 Jul 19;7(29):46127-46141; De and Dey, Int J Mol Sci. 2019 Nov 15;20(22):5732).

[0194] ARID1A loss is associated with activation of the PI-3K / Akt / mTOR pathway (Mullen et al., Cancer Treatment Reviews, 2021, 100, 102287). Loss of ARID1A expression also leads to delayed mitosis and chromosome separation. It has been shown that silencing of ARID1A in gastric cancer, ovarian cancer, glioma, and colon cancer cells activates phosphorylation of Akt and PI3K (Zeng et al., Head & Neck Oncology. 2013; 5 (1): 6; Xie et al., Tumour Biol. August 2014; 35 (8): 7921-7; Takeda et al., Oncology Reports, 2016, 35: 607-613; Zhang et al., Oncotarget. July 2016 19; 7 (29): 46127-46141), which indicates that there is a relationship between ARID1A deficiency and PI3K / Akt pathway activation.

[0195] Interestingly, rhabdoid tumors and ARID1A mutant ovarian cell carcinomas are dependent on RTK signaling, including platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and Met.

[0196] AT-rich interaction domain 2 (ARID2, sometimes referred to as BAF200) is a homologous subunit of the human SWI / SNF complex and also binds to DNA (Mullen et al., Cancer Treatment Reviews, 2021, 100, 102287). ARID2 is a subunit of the PBAF chromatin remodeling complex (part of the SWI / SNF complex family), which promotes ligand-dependent transcriptional activation through nuclear receptors. Mutation studies have revealed that ARID2 is an important tumor suppressor in many cancer subtypes. ARID2 mutations are also associated with various cancers and are particularly common in hepatocellular carcinoma and melanoma. ARID2 mutations occur in urothelial carcinoma and melanoma, and patients can benefit from immune checkpoint inhibitors.

[0197] Without wishing to be bound by any particular theory, the inventors have observed that ARID1A mutant and / or ARID2 mutant colorectal cancers are particularly susceptible to treatment with a combination of an IGF1R inhibitor and an Akt inhibitor. Therefore, the inventors believe that ARID1A or ARID2 mutations may provide a powerful genetic biomarker of efficacy in colorectal cancer patients. See, e.g., Examples 2 and Figure 5 .

[0198] IRS4

[0199] The human insulin receptor substrate 4 (IRS4) gene encodes the IRS4 protein. The IRS4 protein is a cytoplasmic protein that contains many potential tyrosine and serine / threonine phosphorylation sites. The IRS4 protein is phosphorylated by the insulin receptor tyrosine kinase after receptor stimulation.

[0200] Without wishing to be bound by any particular theory, the inventors have also observed that ARID1A mutant and / or ARID2 mutant colorectal cancers (which are also IRS4 wild-type colorectal cancers) are particularly susceptible to treatment with a combination of an IGF1R inhibitor and an Akt inhibitor. See, e.g., Examples 2 and Figure 6 .

[0201] Thus, in some cases, the present invention relates to a method for treating colorectal cancer in a patient, wherein the colorectal cancer is ARID1A mutant and / or ARID2 mutant, and IRS4 wild-type colorectal cancer.

[0202] The features disclosed in the foregoing description, in the appended claims or in the drawings, expressed in their specific form or, where appropriate, in the form of a means for performing the disclosed function or a method or process for obtaining the disclosed results, may be used alone or in any combination of such features to implement the invention in its various forms.

[0203] Although the present invention has been described in conjunction with the above exemplary embodiments, it will be apparent to those skilled in the art that many equivalent modifications and variations will be apparent after obtaining this disclosure. Therefore, the above exemplary embodiments of the present invention should be considered illustrative rather than restrictive. Various changes may be made to the embodiments without departing from the spirit and scope of the present invention.

[0204] To avoid any doubt, any theoretical explanations provided herein are for the purpose of enhancing the reader's understanding. The inventors do not wish to be bound by any of these theoretical explanations.

[0205] Any section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0206] Throughout this specification, including the appended claims, unless the context requires otherwise, the words "comprise" and "comprising" and variations such as "comprises", "comprising" and "including", will be understood to mean the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

[0207] It must be noted that, as used in the specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Ranges may be expressed herein as from "about" one particular value and / or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when a value is expressed as an approximation by using the preposition "about", it is understood that the particular value constitutes another embodiment. The term "about" in relation to a numerical value is optional and, for example, means + / - 10%.

[0208] Example

[0209] Example 1

[0210] Lincitinib or BMS-754807+MK-2206 in breast, colon, and pancreatic cancer cell lines

[0211] Lincitinib was screened in combination with MK-2206 in 51 breast cancer cell lines, 45 colon cancer cell lines, and 29 pancreatic cancer cell lines. BMS-754807 was screened in combination with MK-2206 in 45 colon cancer cell lines. For efficient screening, we used a 2×7 concentration matrix or "anchor" approach. We screened each anchor compound at two optimized concentrations, and a discontinuous 1,000-fold (7-point) dose-response curve of library compounds. Viability was read using CellTiter-Glo after 72 hours of drug treatment, and drug responses were fit for single-agent and combination responses. Viability measurements for single agents and combinations were fit by cell line, and multiple parameters were derived, including: 1) anchor viability effect, 2) viability effect of the library and combination at the highest library concentration used (library E max and combination E max ), and 3) generate a 50% reduction in viability of the pool and combination (IC 50 We compared the observed combination responses of cells with those predicted by the Bliss independence model based on the activity of the monotherapies and compared the potency (ΔIC 50 ; i.e. increased sensitivity) or efficacy (ΔE max Drug combinations were classified based on changes in the concentration of the combination beyond the Bliss independence model (Bliss, Annals of Applied Biology, 1939, 26(3), 585-615). If at any anchor concentration, the combination IC 50 or E maxIf the reduction in activity is 1 / 8 of Bliss or 20% more than Bliss, respectively, the inventors classified the combination-cell line pair as synergistic. The inventors observed that lincitinib + MK-2206 has a high synergistic rate in colon cancer cells (see Table 1). The combination was screened in the anchor and library directions, and the first named compound was the anchor compound.

[0212] The inventors observed that the synergy and activity of IGF1Ri BMS-754807 was much lower (see Table 2). The synergy rate in colon was also a subset of KRAS mut (n=24) and KRAS wt (n=21) cell lines (see Table 3).

[0213] Table 1

[0214]

[0215] *The first compound listed is the anchor compound. This combination was tested in both orientations.

[0216] Table 2

[0217]

[0218]

[0219] Table 3

[0220]

[0221] Example 2

[0222] Lincitinib or BMS-754807+MK-2206 in breast, colon, and pancreatic cancer cell lines

[0223] method:

[0224] Lincitinib was screened in combination with MK-2206 in 51 breast cancer cell lines, 45 colon cancer cell lines, and 29 pancreatic cancer cell lines. BMS-754807 was screened in combination with MK-2206 in 45 colon cancer cell lines. For efficient screening, we used a 2×7 concentration matrix or "anchor" approach. The inventors screened each anchor compound at two optimized concentrations, and a discontinuous 1,000-fold (7-point) dose-response curve of library compounds. CellTiter-Glo was used to read the viability after 72 hours of drug treatment, and the drug responses of single agents and combination responses were fit. Viability measurements of single agents and combinations were fitted by cell line, and multiple parameters were derived, including: 1) anchor viability effect, 2) viability effect of the library and combination at the highest library concentration used (library E max and combination E max), and 3) the estimated pool drug concentrations that produced a 50% reduction in activity (IC 50 The inventors compared the observed combination responses of cells with those predicted by the Bliss independence model based on the activity of the monotherapies and compared the responses based on the potency (ΔIC 50 ; i.e. increased sensitivity) or efficacy (ΔE max Drug combinations were classified based on changes in the concentration of the combination beyond the Bliss independence model (Bliss, Annals of Applied Biology, 1939, 26(3), 585-615). If at any anchor concentration, the combination IC 50 or E max If the reduction in viability was 1 / 8 of that of Bliss or 20% more than that of Bliss, respectively, the inventors classified the combination-cell line pair as synergistic.

[0225] result:

[0226] Mutation of ARID1A (mutant n=10; wild-type n=35) sensitized colon cancer cell lines to treatment with MK-2206+linsitinib. Compared with ARID1A wild-type cells, efficacy (ΔIC 50 ) and efficacy (ΔE max ) (see Figure 1 A and 1B). This change was also observed independently in ARID2 mutants (mutant n = 7; wild type n = 38) (see Figure 2 A and 2B).

[0227] The ARID1A and ARID2 mutant populations did not completely overlap, and combining these two markers as "ARID1A mutant or ARID2 mutant" (n=13) improved the ability of either biomarker alone to distinguish cell lines with high synergy from those with low synergy (see Figure 5 ).

[0228] The mutation status of IRS4 alone showed some correlation with the response of colon cancer cell lines to treatment with MK-2206+linsitinib (see Figure 3 A and 3B). IRS4 is directly downstream of IGF1R, and IRS4 mutant cell lines were generally less sensitive to this combination. All IRS4 mutant cell lines were observed to have a Log2ΔIC<3 50 (define the cutoff value for synergy) (see Figure 3 A and Figure 4 ), which raised the selection to combine IRS4 with ARID1A and ARID2 as a biomarker for MK-2206+linsitinib (see Figure 6 ). In fact, the combination of ARID1A mutant or ARID2 mutant and IRS4 wild-type improved the ability of ARID1A mutant or ARID2 mutant to distinguish cell lines with high synergy from those with low synergy (see Figure 5 and 6 comparison).

[0229] Example 3

[0230] Other IGF1R+Akt inhibitor combinations in colon cancer cell lines

[0231] method:

[0232] Screening was performed in 4 colon cancer cell lines (LS-180, HCC2998, SW1417, SW837) using a 7×7 matrix approach, generating 49 wells of data per cell line / drug combination. For each combination, an Akt inhibitor was combined with an IGF1R inhibitor over a discrete 1,000-fold (7-point) dose range. Viability was measured using CellTiter-Glo reagent 72 hours after drug treatment. Viability measurements for single agents and combinations were fitted by cell line, and multiple parameters were derived, including single agent values ​​and a range of synergy scores.

[0233] For all 49 concentration combinations measured, Bliss excess was calculated by comparing the observed combined response of the cells to the response predicted by the Bliss independence model based on the activity of the monotherapies. The "Bliss window" is reported as the highest Bliss excess value measured in 25 possible 3 × 3 sub-matrices or "windows" in the 7 × 7 dose matrix.

[0234] In addition, the HSA (highest single agent) excess measured for all 49 concentration combinations was calculated by comparing the observed combined response of the cells to the highest single agent response in either Drug A or Drug B, whichever was highest. The “HSA window” is reported as the highest HSA excess value measured in 25 possible 3×3 sub-matrices or “windows” within the 7×7 dose matrix.

[0235] result:

[0236] The screen included three Akt inhibitors (MK-2206, patasertib and afloresetib), each of which was combined with one of five IGF1R inhibitors (BMS-536924, brigatinib, GSK1904529A, linsitinib and XL228). For the purpose of objectively identifying synergistic combinations, if the Bliss window is greater than 0.116, the cell line is judged to show synergy for the combination. This arbitrary cutoff is based on calculating the average Bliss window of all samples, plus 1× standard deviation. More generally, the higher the Bliss window score, the stronger the synergy.

[0237] Ten combinations showed synergy in at least one biomarker-positive cell line (LS-180 or HCC2998) and in Figure 7 (AJ). The biomarker here is "ARID1A mutant or ARID2 mutant and IRS4 wild type" as described above. Figure 7 The ten combinations shown were classified as synergistic according to the above criteria and in all cases showed enhanced synergy in biomarker positive cell lines relative to biomarker negative lines.

[0238] Example 4

[0239] Lincitinib + Akt inhibitor combination in colon cancer cell line LS-180

[0240] method:

[0241] Compounds were tested in the colon cancer cell line LS-180 using a 7×7 matrix approach, generating data from 49 wells per cell line / drug combination. For each combination, an Akt inhibitor was combined with an IGF1R inhibitor over a discrete 1,000-fold (7-point) dose range. Viability was measured using CellTiter-Glo reagent 72 hours after drug treatment. Viability measurements for single agents and combinations were fitted by cell line, and multiple parameters were derived, including single agent values ​​and a range of synergy scores.

[0242] The viability measurements of the single agents and the combination were fitted for each combination and multiple parameters were derived, including: 1) the viability effect of the single agent, 2) the viability effect of the single agent and the combination at the highest concentration used (E max ), and 3) the estimated drug concentration that produced a 50% reduction in viability (IC 50 We compared the observed combination responses of cells with those predicted by the Bliss independence model based on the activity of the monotherapies and compared the responses based on the potency (ΔIC 50 ; i.e. increased sensitivity) or efficacy (ΔE maxDrug combinations were classified based on changes in activity beyond the Bliss independence model (Bliss, Annals of Applied Biology, 1939, 26(3), 585-615) in terms of serotonin (i.e., decreased cell viability).

[0243] result:

[0244] Four Akt inhibitors (MK-2206, miracetam, capasitinib, and BAY1125976) were tested in combination with a single IGF1R inhibitor (lincitinib) in LS-180 cells. Note that this cell line is positive for biomarkers where the biomarkers are ARID1A mutant or ARID2 mutant and IRS4 wild type. Table 4 below shows the ΔIC achieved for each combination from two independent replicates 50 and ΔE max All four Akt inhibitors showed consistent synergy with lincitinib in this cell line, exhibiting an IC 50 at least 5-fold change.

[0245] Table 4

[0246]

[0247] Example 5

[0248] Lincitinib and MK-2206 in endometrial and ovarian cancer cell lines

[0249] method:

[0250] Screening was performed in three endometrial cancer cell lines (MFE-280, MFE-296, and RL95-2) and three ovarian cancer cell lines (OV-90, A2780, and OAW-42) using a 7×7 matrix approach, generating 49 wells of data for each cell line / drug combination. MK-2206 was combined with lincitinib over a discrete 1,000-fold (7-point) dose range. Viability was measured 72 hours after drug treatment using CellTiter-Glo reagent. Viability measurements for single agents and combinations were fitted by cell line, and multiple parameters were derived, including single agent values ​​and a range of synergy scores.

[0251] Viability measurements of single agents and combinations were fitted per cell line and derived for multiple parameters including: 1) anchor viability effect, 2) viability effect of pools and combinations at the highest pool concentration used (pool E max and combination E max ), and 3) the estimated pool drug concentrations that produced a 50% reduction in activity (IC 50We compared the observed combination responses of cells with those predicted by the Bliss independence model based on the activity of the monotherapies and compared the responses based on the potency (ΔIC 50 ; i.e. increased sensitivity) or efficacy (ΔE max Drug combinations were classified based on changes in activity beyond the Bliss independence model (Bliss, Annals of Applied Biology, 1939, 26(3), 585-615) in terms of serotonin (i.e., decreased cell viability).

[0252] result:

[0253] For each cancer type, two ARID1A mutant cell lines and one ARID1A wild-type cell line were selected for testing. Synergy in these two cancer types was not as clear as in colorectal cancer, however, there was a correlation between ARID1A mutation status and synergy. For both endometrial and ovarian cancer cell lines, as measured by synergy, deltaIC 50 (i.e., ΔIC 50 ) and deltaE max (i.e. ΔE max ) showed greater synergy between lincitinib and MK-2206 in ARID1A mutant cell lines compared with ARID1A wild-type cell lines ( Figure 8 ).

[0254] References

[0255] Many publications are cited above to more fully describe and disclose the present invention and the current state of the art to which the present invention belongs. The complete citations of these references are provided below. The full text of each of these references is incorporated herein.

[0256] Berge et al., J Pharm Sci, 1977 66(1) p 1

[0257] Bergqvist et al., Acta Oncologica, 56:3, 441-447, DOI: 10.1080 / 0284186X.2016.1253866

[0258] Biesecker et al., Cold Spring Harb Mol Case Study, 2020 Feb 3;6(1):a004549; doi:10.1101 / mcs.a004549

[0259] Blagden et al., Clin Cancer Res (2019) 25(5): 1472–1478

[0260] Bliss,Annals of Applied Biology,1939,26(3),585-615

[0261] Chung et al., JAMA Oncol., 2017 Apr 1;3(4):516-522

[0262] Crabb et al., J Clin Oncol. 2021 Jan 20;39(3):190–201

[0263] Davis et al., Oncologist, 2018 Dec;23(12):1409-e140

[0264] De and Dey, Int J Mol Sci. 2019 Nov 15;20(22):5732

[0265] Fassnacht et al., Lancet Oncol., 2015 Apr;16(4):426-435

[0266] Huang et al., Mod Pathol, 2014 Jul;27(7):983-90

[0267] Hyman et al., Cancer Res(2018)78(13_Supplement):CT035; https: / / doi.org / 10.1158 / 1538-7445.AM2018-CT035

[0268] Kim et al., Future Oncology 2021 17:14,1709-1719

[0269] Kim et al., The Lancet Oncology, Vol. 18, No. 10, 2017, pp. 1360-1372

[0270] Kostaras et al. Br J Cancer. 2020 Aug;123(4):542-555

[0271] Lazaro et al. Biochem Soc Trans. 2020 Jun 30;48(3):933-943

[0272] Mittal et al., 2020, Nat Rev Clin Oncol., 2020, July 17(7): 435-448

[0273] Mullen et al., Cancer Treatment Reviews, 2021, 100, 102287

[0274] Oliveira et al., Ann Oncol, 2019 Aug 1;30(8):1289-1297. doi:10.1093 / annonc / mdz177

[0275] Puzanov et al., Clin Cancer Res., 2015 Feb 15;21(4):701-711

[0276] Remington's Pharmaceutical Sciences, 20th Edition, 2000, pub. Lippincott, Williams & Wilkins

[0277] Samartzis et al., Int. J. Mol. Sci., 2013, 14, 188824-18849

[0278] Samartzis et al., Oncotarget. 2014 Jul 30;5(14):5295-303

[0279] Schneeweiss et al., Cancers 2019, 11(12), 1987; https: / / doi.org / 10.3390 / cancers11121987

[0280] Smith et al.,Journal of Clinical Oncology 2010 28:15_suppl,3105-3105

[0281] Spencer et al., Blood (2014) 124(14): 2190–2195

[0282] Takeda et al., Oncology Reports, 2016, 35: 607-613

[0283] Tessiri et al., PeerJ, 2022, 10: e12750

[0284] Tolcher et al., Cancer Chemother Pharmacol, 2020 Apr;85(4):673-683

[0285] Umehara et al.Therapeutic Advances in Medical Oncology.2018;10.doi:10.1177 / 1758835918786858

[0286] Xie et al., Tumour Biol. 2014 Aug;35(8):7921-7

[0287] Xing et al., Breast Cancer Res., 2019 Jul 5;21(1):78

[0288] Yap et al., J Clin Oncol., 2011 Dec 10;29(35):4688-4695

[0289] Zeng et al., Head & Neck Oncology. 2013; 5(1): 6

[0290] Zhang et al., Oncotarget. 2016 Jul 19;7(29):46127-46141

[0291] Zhu et al., Cancer Biology & Therapy, 2022, Vol. 23, No. 1, 104-111

[0292] https: / / clinicaltrials.gov / ct2 / show / NCT01902173

[0293] https: / / clinicaltrials.gov / ct2 / show / study / NCT02930109

[0294] https: / / clinicaltrials.gov / ct2 / show / NCT04305496

[0295] https: / / www.drugdiscoverytrends.com / arqule-reports-positive-phase-i-data-in-haematological-malignancies-study /

[0296] https: / / www.fda.gov / medical-devices / in-vitro-diagnostics / list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools

[0297] www.genenames.org

[0298] https: / / ir.exelixis.com / news-releases / news-release-details / exelixis-reports-positive-phase-1-data-xl228-ash-annual-meeting

[0299] https: / / www.globenewswire.com / en / news-release / 2019 / 05 / 08 / 1819580 / 0 / en / Cotinga-Pharmaceuticals-Releases-Early-Interim-Data-of-Phase-1b-2a-Combination-Trial-of-COTI-2-in-Solid-Tumors.html

[0300] https: / / smallcaps.com.au / prescient-therapeutics-encouraging-efficacy-results-leading-cancer-drug-candidate-ptx-200 /

[0301] For standard molecular biology techniques, see Sambrook, J., Russel, DW Molecular Cloning, A Laboratory Manual. 3rd ed. 2001, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.

[0302] Priority Clause

[0303] 1. A combination of lincitinib or AXL-1717 and an Akt inhibitor for use in a method of treating colorectal cancer.

[0304] 2. The combination for use according to clause 1, wherein the combination is lincitinib and an Akt inhibitor.

[0305] 3. A combination for use according to clause 1 or 2, wherein the Akt inhibitor is selected from MK-2206, capasertib, patasertib, aflorasertib, mirasertib, eupsitib, triciribine, PTX-200, TAS-117, COTI-2, LY-2503029 and MK-4440.

[0306] 4. The combination for use according to clause 3, wherein the Akt inhibitor is selected from MK-2206, patasertib and aflorasertib.

[0307] 5. The combination for use according to clause 3, wherein the Akt inhibitor is MK-2206.

[0308] 6. The combination for use according to clause 1, wherein the combination is lincitinib and MK-2206.

[0309] 7. A combination for use according to any preceding clause, wherein the cancer is KRAS mutant colorectal cancer.

[0310] 8. A combination for use according to clause 7, wherein the cancer comprises cells with alterations at ERCC3.

[0311] 9. The combination for use according to clause 8, wherein the alteration is a mutation.

[0312] 10. The combination for use according to clause 8, wherein the alteration is a deletion of ERCC3.

[0313] 11. The combination for use according to clause 10, wherein the deletion of ERCC3 is a homozygous deletion.

[0314] 12. A combination for use according to any preceding clause, wherein lincitinib or AXL-1717 and the Akt inhibitor are administered separately.

Claims

1. A combination of an IGF1R inhibitor and an Akt inhibitor for use in a method of treating cancer, wherein the cancer is selected from colorectal cancer, ovarian cancer and endometrial cancer.

2. An IGF1R inhibitor for use in a method of treating cancer in a patient, wherein the cancer is selected from colorectal cancer, ovarian cancer, and endometrial cancer, and wherein the IGF1R inhibitor is administered to the patient in combination with an Akt inhibitor.

3. An Akt inhibitor for use in a method of treating cancer in a patient, wherein the cancer is selected from colorectal cancer, ovarian cancer, and endometrial cancer, and wherein the IGF1R inhibitor is administered to the patient in combination with an IGF1R inhibitor.

4. The combination for use according to claim 1, the IGF1R inhibitor for use according to claim 2 or the Akt inhibitor for use according to claim 3, wherein the cancer is colorectal cancer.

5. A combination for use according to any one of the preceding claims, an IGF1R inhibitor or an Akt inhibitor, wherein the IGF1R inhibitor is selected from linsitinib, GSK1904529A, XL228, BMS-536924, BMS-754807, brigatinib, AXL-1717 and KW-2450; or is an IGF1R antibody.

6. The combination for use according to claim 5, an IGF1R inhibitor or an Akt inhibitor, wherein the IGF1R inhibitor is selected from lincitinib, GSK1904529A, XL228, BMS-536924, BMS-754807, brigatinib, AXL-1717 and KW-2450.

7. The combination for use according to claim 5, an IGF1R inhibitor or an Akt inhibitor, wherein the IGF1R inhibitor is selected from lincitinib, GSK1904529A, XL228, BMS-536924, BMS-754807, brigatinib and AXL-1717.

8. The combination for use according to claim 5, an IGF1R inhibitor or an Akt inhibitor, wherein the IGF1R inhibitor is selected from lincitinib, GSK1904529A, XL228, BMS-536924 and brigatinib.

9. The combination for use according to claim 5, an IGF1R inhibitor or an Akt inhibitor, wherein the IGF1R inhibitor is selected from lincitinib, GSK1904529A, XL228 and BMS-536924.

10. The combination for use according to claim 5, an IGF1R inhibitor or an Akt inhibitor, wherein the IGF1R inhibitor is selected from lincitinib and GSK1904529A.

11. The combination for use according to claim 5, an IGF1R inhibitor or an Akt inhibitor, wherein the IGF1R inhibitor is lincitinib.

12. A combination for use according to any one of the preceding claims, an IGF1R inhibitor or an Akt inhibitor, wherein the Akt inhibitor is an allosteric Akt inhibitor.

13. The combination for use according to any one of claims 1 to 11, an IGF1R inhibitor or an Akt inhibitor, wherein the Akt inhibitor is an ATP-competitive Akt inhibitor.

14. A combination for use according to any one of claims 1 to 11, an IGF1R inhibitor or an Akt inhibitor, wherein the Akt inhibitor is selected from MK-2206, capasertib, patasertib, aflorasertib, mirasertib, eupsitib, triciribine, PTX-200, TAS-117, COTI-2, LY-2503029, MK-4440 and BAY1125976.

15. The combination for use according to claim 14, an IGF1R inhibitor or an Akt inhibitor, wherein the Akt inhibitor is selected from MK-2206, capasertib, patasertib, aflorasertib, mirasertib and BAY1125976.

16. The combination for use according to claim 14, an IGF1R inhibitor or an Akt inhibitor, wherein the Akt inhibitor is selected from MK-2206, capasitinib, miranitinib and BAY1125976.

17. The combination for use according to claim 14, an IGF1R inhibitor or an Akt inhibitor, wherein the Akt inhibitor is selected from MK-2206, patasertib and aflorasertib.

18. The combination for use according to claim 14, an IGF1R inhibitor or an Akt inhibitor, wherein the Akt inhibitor is selected from MK-2206 and aflupirtimide.

19. The combination for use according to claim 14, an IGF1R inhibitor or an Akt inhibitor, wherein the Akt inhibitor is MK-2206.

20. A combination for use according to any one of the preceding claims, an IGF1R inhibitor or an Akt inhibitor, wherein the IGF1R inhibitor is lincitinib and the Akt inhibitor is MK-2206.

21. The combination for use according to any one of the preceding claims, an IGF1R inhibitor or an Akt inhibitor, wherein the cancer is an ARID1A mutant and / or an ARID2 mutant cancer.

22. The combination for use according to claim 21, an IGF1R inhibitor or an Akt inhibitor, wherein the cancer is an ARID1A mutant cancer.

23. The combination for use according to claim 21, an IGF1R inhibitor or an Akt inhibitor, wherein the cancer is an ARID2 mutant cancer.

24. The combination for use according to claim 21, an IGF1R inhibitor or an Akt inhibitor, wherein the cancer is an ARID1A mutant cancer and an ARID2 mutant cancer.

25. The combination for use according to any one of claims 21 to 24, an IGF1R inhibitor or an Akt inhibitor, wherein the cancer is an IRS4 wild-type cancer.

26. The combination for use according to claim 25, an IGF1R inhibitor or an Akt inhibitor, wherein the cancer is ARID1A mutant and / or ARID2 mutant and IRS4 wild-type colorectal cancer.

27. The combination for use according to claim 22, an IGF1R inhibitor or an Akt inhibitor, wherein the cancer is ARID1A mutant ovarian cancer.

28. The combination for use according to claim 22, an IGF1R inhibitor or an Akt inhibitor, wherein the cancer is ARID1A mutant endometrial cancer.

29. The combination for use according to any one of claims 26 to 28, an IGF1R inhibitor or an Akt inhibitor, wherein the IGF1R inhibitor is lincitinib and the Akt inhibitor is MK-2206.

30. The combination for use according to any one of the preceding claims, an IGF1R inhibitor or an Akt inhibitor, wherein the cancer is a KRAS mutant cancer.

31. A combination for use according to any one of the preceding claims, an IGF1R inhibitor or an Akt inhibitor, wherein the IGF1R inhibitor and the Akt inhibitor are administered separately.